 |
 |
 |
 |
 |
 |
Treatment Name: |
 |
A Phase I dose escalation trial of Temodar that will attempt to determine the maximum tolerated dose of Temodar (Temozolomide) when given by prolonged oral exposure to children with recurrent or progressive brain tumors. |
 |
 |
 |
 |
 |
 |
Keywords: |
 |
Temodar |
 |
 |
 |
 |
Phase: |
 |
Phase 1 |
 |
 |
 |
 |
 |
 |
Treatment ID#s: |
 |
VT616
|
 |
 |
 |
 |
Age Group: |
 |
Pediatric Only |
 |
 |
 |
 |
 |
 |
Min Karnofsky Score: |
 |
Not Specified |
 |
 |
 |
 |
Conditions: |
 |
Newly Diagnosed: N
Recurrent: Y
Prior Surgery is Allowed Prior Radiation is Allowed Prior Chemotherapy is Sometimes Allowed |
 |
 |
 |
 |
 |
 |
Last Updated: |
 |
12/03/2005 |
 |
 |
 |
 |
Tumor Types: |
 |
Anaplastic Astrocytoma Brainstem Glioma Craniopharyngioma Ependyoma Ganglioglioma Glioblastoma Multiforme Gliosarcoma Low Grade Glioma Medulloblastoma Meningioma Mixed Glioma Oligodendroglioma High Grade Oligodendroglioma Low Grade Optic Glioma PNET Tumor |
 |
 |
 |
 |
 |
 |
 |
Comments: |
 |
Patients will receive Temodar for 42 consecutive days followed by a 28 day rest. Eligible patients must be no greater than 18 years of age at the time of study entry. Subsequent courses are permissible once a patient has completed 42 days of therapy followed by 28 days of rest. Each patient may continue to receive Temodar for up to 12 courses or until disease progression. |
 |
 |
 |
 |
 |
 |
Treatment Type: |
 |
Chemotherapy. |
 |
 |
 |
 |
Contact: |
 |
NYU Medical Center Jeffrey Allen, MD 317 E. 34th Street, 10th Floor New York, NY 10016 Phone:212-263-6725 Click here to send an email |
 |
 |